![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » CHRONOGEN ANNOUNCES A PARTNERSHIP WITH SOSEI FOR THE SCREENING OF THE SOSEI DRUG REPROFILING PLATFORM COMPOUND LIBRARY
CHRONOGEN ANNOUNCES A PARTNERSHIP WITH SOSEI FOR THE SCREENING OF THE SOSEI DRUG REPROFILING PLATFORM COMPOUND LIBRARY
Chronogen, a drug discovery company developing therapeutics to treat age-dependent diseases has announced an agreement with Sosei, a leading Japanese biopharmaceutical company focused on drug development. Under this agreement, Chronogen will screen the library of Sosei's Drug Reprofiling Platform in a variety of Chronogen's proprietary, phenotype- based, in vivo screening assays in the nematode C. elegans. For its Drug Reprofiling Platform, Sosei has acquired a collection of drugs from a number of Japanese pharmaceutical companies.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct